allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq

FDA Drug Profile — TREGZI

allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including TREGZI. Available dosage form: kit.

Drug details

Generic Name
allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
Brand Names
TREGZI
Application Number
BLA125868
Sponsor
Orca Biosystems Inc.
NDC Codes
2
Dosage Forms
KIT

Indications and Usage

1 INDICATIONS AND USAGE TREGZI is indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease-free survival, in the treatment of adults with hematological malignancies. TREGZI™ is an allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cells and T cells indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGVHD)-free survival, in the treatment of adults with hematological malignancies. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.